Sartorius Stedim Bio

Sartorius Stedim Biotech reports revenue of €2.6 billion for the first nine months of 2025, a currency-adjusted increase of 7.5%. Adjusted EBITDA rose 12.8% to €774 million, and the EBITDA margin climbed to 29.7%. Drivers were consumables, bioanalytics and progress in manufacturing processes; the company expects around 7% revenue growth for 2025 and about 9% for the Bioprocess Solutions segment. Management sees risks in tariffs, US competition and potential supply-chain strains; a Capital Markets Day to update long-term targets is planned for Q1 2026. » Więcej na de.investing.com

Sartorius Stedim Biotech will release results for the quarter ended September 30, 2025 on October 16, 2025. Analyst consensus (5 analysts) expects EPS of €0.982, which would represent an increase of 277.69% versus €0.260 a year earlier. Four analysts forecast revenue of an average €697.0 million versus €655.4 million in the same quarter last year. For the current fiscal year, average estimates are EPS of €4.44 and revenue of €2.97 billion. » Więcej na finanzen.net

Sartorius Stedim Biotech significantly surpassed profit and revenue expectations in the second quarter of 2025, driven by strong growth in its Bioprocessing Solutions division. Earnings per share reached $1.22, beating forecasts by 17.31%, while revenue rose to $884.3 million, exceeding expectations by 22.13%. Despite the positive results, the share price remained stable, and the company continues to project optimistic growth for the full year 2025. » Więcej na de.investing.com